BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gentile I, Buonomo AR, Borgia F, Zappulo E, Castaldo G, Borgia G. MK-5172 : a second-generation protease inhibitor for the treatment of hepatitis C virus infection. Expert Opin Investig Drugs. 2014;23:719-728. [PMID: 24666106 DOI: 10.1517/13543784.2014.902049] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 3.4] [Reference Citation Analysis]
Number Citing Articles
1 Chayama K, Imamura M, Hayes CN. Hepatitis C virus treatment update - A new era of all-oral HCV treatment. Advances in Digestive Medicine 2016;3:153-60. [DOI: 10.1016/j.aidm.2016.03.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
2 Gentile I, Buonomo AR, Zappulo E, Borgia G. Discontinued drugs in 2012 – 2013: hepatitis C virus infection. Expert Opinion on Investigational Drugs 2015;24:239-51. [DOI: 10.1517/13543784.2015.982274] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 3.5] [Reference Citation Analysis]
3 Lawitz EJ, O'Riordan WD, Asatryan A, Freilich BL, Box TD, Overcash JS, Lovell S, Ng TI, Liu W, Campbell A, Lin CW, Yao B, Kort J. Potent Antiviral Activities of the Direct-Acting Antivirals ABT-493 and ABT-530 with Three-Day Monotherapy for Hepatitis C Virus Genotype 1 Infection. Antimicrob Agents Chemother 2015;60:1546-55. [PMID: 26711747 DOI: 10.1128/AAC.02264-15] [Cited by in Crossref: 33] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
4 Gentile I, Buonomo AR, Zappulo E, Minei G, Morisco F, Borrelli F, Coppola N, Borgia G. Asunaprevir, a protease inhibitor for the treatment of hepatitis C infection. Ther Clin Risk Manag. 2014;10:493-504. [PMID: 25061308 DOI: 10.2147/tcrm.s66731] [Cited by in Crossref: 18] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
5 Campos GRF, Bittar C, Jardim ACG, Shimizu JF, Batista MN, Paganini ER, Assis LR, Bartlett C, Harris M, Bolzani VDS, Regasini LO, Rahal P. Hepatitis C virus in vitro replication is efficiently inhibited by acridone Fac4. J Gen Virol 2017;98:1693-701. [PMID: 28699869 DOI: 10.1099/jgv.0.000808] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
6 Cento V, Chevaliez S, Perno CF. Resistance to direct-acting antiviral agents: clinical utility and significance. Curr Opin HIV AIDS 2015;10:381-9. [PMID: 26248125 DOI: 10.1097/COH.0000000000000177] [Cited by in Crossref: 19] [Cited by in F6Publishing: 10] [Article Influence: 3.2] [Reference Citation Analysis]
7 Elbaz T, El-Kassas M, Esmat G. New era for management of chronic hepatitis C virus using direct antiviral agents: A review. J Adv Res. 2015;6:301-310. [PMID: 26257927 DOI: 10.1016/j.jare.2014.11.004] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 2.6] [Reference Citation Analysis]
8 Sulejmani N, Jafri SM. Grazoprevir/elbasvir for the treatment of adults with chronic hepatitis C: a short review on the clinical evidence and place in therapy. Hepat Med 2018;10:33-42. [PMID: 29765256 DOI: 10.2147/HMER.S130103] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
9 Gentile I, Borgia G. Vertical transmission of hepatitis B virus: challenges and solutions. Int J Womens Health. 2014;6:605-611. [PMID: 24966696 DOI: 10.2147/ijwh.s51138] [Cited by in Crossref: 10] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
10 Gentile I, Scotto R, Zappulo E, Buonomo AR, Pinchera B, Borgia G. Investigational direct-acting antivirals in hepatitis C treatment: the latest drugs in clinical development. Expert Opinion on Investigational Drugs 2016;25:557-72. [DOI: 10.1517/13543784.2016.1161023] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
11 Guan Y, Sun H, Pan P, Li Y, Li D, Hou T. Exploring resistance mechanisms of HCV NS3/4A protease mutations to MK5172: insight from molecular dynamics simulations and free energy calculations. Mol BioSyst 2015;11:2568-78. [DOI: 10.1039/c5mb00394f] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
12 Smolders EJ, de Kanter CT, van Hoek B, Arends JE, Drenth JP, Burger DM. Pharmacokinetics, Efficacy, and Safety of Hepatitis C Virus Drugs in Patients with Liver and/or Renal Impairment. Drug Saf. 2016;39:589-611. [PMID: 27098247 DOI: 10.1007/s40264-016-0420-2] [Cited by in Crossref: 53] [Cited by in F6Publishing: 53] [Article Influence: 10.6] [Reference Citation Analysis]
13 Sulejmani N, Jafri SM, Gordon SC. Pharmacodynamics and pharmacokinetics of elbasvir and grazoprevir in the treatment of hepatitis C. Expert Opin Drug Metab Toxicol. 2016;12:353-361. [PMID: 26849059 DOI: 10.1517/17425255.2016.1148685] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
14 Cada DJ, Kim AP, Baker DE. Elbasvir/Grazoprevir. Hosp Pharm. 2016;51:665-686. [PMID: 27698508 DOI: 10.1310/hpj5108-665] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
15 Gentile I, Coppola N, Buonomo AR, Zappulo E, Borgia G. Investigational nucleoside and nucleotide polymerase inhibitors and their use in treating hepatitis C virus. Expert Opin Investig Drugs. 2014;23:1211-1223. [PMID: 24848437 DOI: 10.1517/13543784.2014.921680] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 3.1] [Reference Citation Analysis]
16 Gondeau C, Pageaux GP, Larrey D. Hepatitis C virus infection: Are there still specific problems with genotype 3? World J Gastroenterol 2015; 21(42): 12101-12113 [PMID: 26576095 DOI: 10.3748/wjg.v21.i42.12101] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
17 Zálešák F, Kováč O, Lachetová E, Št'astná N, Pospíšil J. Unified Approach to Benzo[d]thiazol-2-yl-Sulfonamides. J Org Chem 2021;86:11291-309. [PMID: 34479409 DOI: 10.1021/acs.joc.1c00317] [Reference Citation Analysis]
18 Borgia G, Maraolo AE, Buonomo AR, Scotto R, Gentile I. The therapeutic potential of new investigational hepatitis C virus translation inhibitors. Expert Opin Investig Drugs 2016;25:1209-14. [PMID: 27537604 DOI: 10.1080/13543784.2016.1225036] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
19 Gentile I, Zappulo E, Buonomo AR, Borgia G. Prevention of mother-to-child transmission of hepatitis B virus and hepatitis C virus. Expert Rev Anti Infect Ther. 2014;12:775-782. [PMID: 24840817 DOI: 10.1586/14787210.2014.920254] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
20 Buonomo AR, Scotto R, Coppola C, Pinchera B, Viceconte G, Rapillo CM, Staiano L, Saturnino M, Scarano F, Portunato F, Pisaturo M, De Pascalis S, Martini S, Tosone G, Nappa S, Coppola N, Gentile I. Direct acting antivirals treatment for hepatitis C virus infection does not increase the incidence of de novo hepatocellular carcinoma occurrence: Results from an Italian real-life cohort (LINA cohort). Medicine (Baltimore) 2020;99:e18948. [PMID: 32028404 DOI: 10.1097/MD.0000000000018948] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
21 Gentile I, Buonomo AR, Zappulo E, Borgia G. Interferon-free therapies for chronic hepatitis C: toward a hepatitis C virus-free world? Expert Rev Anti Infect Ther 2014;12:763-73. [PMID: 24918116 DOI: 10.1586/14787210.2014.929497] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 5.3] [Reference Citation Analysis]
22 Gentile I, Zappulo E, Buonomo AR, Scotto R, Borgia G. Asunaprevir for hepatitis C: a safety evaluation. Expert Opin Drug Saf 2015;14:1631-46. [PMID: 26329454 DOI: 10.1517/14740338.2015.1084287] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
23 Gentile I, Maraolo AE, Niola M, Graziano V, Borgia G, Paternoster M. Limiting the access to direct-acting antivirals against HCV: an ethical dilemma. Expert Review of Gastroenterology & Hepatology 2016;10:1227-34. [DOI: 10.1080/17474124.2016.1234375] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
24 Welzel TM, Dultz G, Zeuzem S. Interferon-free antiviral combination therapies without nucleosidic polymerase inhibitors. J Hepatol. 2014;61:S98-S107. [PMID: 25443350 DOI: 10.1016/j.jhep.2014.08.014] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
25 Gentile I, Buonomo AR, Borgia G. Ombitasvir: a potent pan-genotypic inhibitor of NS5A for the treatment of hepatitis C virus infection. Expert Rev Anti Infect Ther. 2014;12:1033-1043. [PMID: 25074011 DOI: 10.1586/14787210.2014.940898] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
26 Gentile I, Zappulo E, Buonomo AR, Maraolo AE, Borgia G. Beclabuvir for the treatment of hepatitis C. Expert Opin Investig Drugs 2015;24:1111-21. [PMID: 26156630 DOI: 10.1517/13543784.2015.1059820] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]